Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials.

ABSTRACT:

Background

Anthracyclines can cause dose-dependent cardiotoxicity that may be irreversible. To minimize cardiotoxic effects, substituting doxorubicin for liposomal doxorubicin (LD) has been explored as a cardioprotective strategy.

Objectives

To describe randomized clinical trials (RCTs) comparing the efficacy and safety of LD with other anthracycline-based regimens.

Methods

We conducted a systematic review and meta-analysis of RCTs comparing LD with other anthracycline-based regimens, using data from Medline, Embase, Emcare, the Cochrane Central Register, and LILACS.

Results

Twelve studies including 3027 patients with breast cancer (6), multiple myeloma (2), lymphoma (2), sarcoma (1), and acute lymphocytic leukemia (1) were included. Most participants (86%) wer

SUBMITTER: Cavalli GD 

PROVIDER: S-EPMC12519849 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature